Evommune Inc
EVMN
84 hedge funds and large institutions have $793M invested in Evommune Inc in 2026 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 10 closing their positions.
270% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 10
136% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 11
70% more capital invested
Capital invested by funds: $466M → $793M (+$328M)
42% more funds holding
Funds holding: 59 → 84 (+25)
9.71% more ownership
Funds ownership: 86.29% → 96% (+9.7%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$30.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$20.3M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$19.2M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$16.4M |
| 5 |
BlackRock
New York
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$8.99M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$8.06M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.62M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$2.45M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.99M |
EVMN Hedge Fund Activity: Q1 2026 in Review
84 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Evommune Inc (EVMN) for Q1 2026, worth a combined $793M — up 70% from $466M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new EVMN positions and 10 closed out — a net gain of 27 holders — while 26 added to existing stakes and 11 trimmed.
The largest buyer was MPM BioImpact, adding an estimated $30.4M. The largest seller was Aberdeen Group, exiting entirely with an estimated $8.99M sold.
- 84 institutional investors held Evommune Inc (EVMN) as of Q1 2026, up from 59 in Q4 2025.
- Funds reported $793M of Evommune Inc stock for Q1 2026, up 70% quarter-over-quarter.
- 37 funds opened new Evommune Inc positions in Q1 2026 and 10 closed out, a net change of +27 holders.
- The largest Evommune Inc buyer in Q1 2026 was MPM BioImpact, an estimated $30.4M added.
- The largest Evommune Inc seller in Q1 2026 was Aberdeen Group, an estimated $8.99M sold.
Based on aggregated 13F filings for Q1 2026.